シンジェンタグループ株式会社

Syngenta Group is a world-leading agricultural technology and crop protection company, established in 2000 through the merger of the agricultural divisions of Novartis and AstraZeneca, and underwent a major organizational restructuring in 2020. Headquartered in Basel, Switzerland, it employs approximately 50,000 people across over 90 countries and regions, achieving revenue of $28.4 billion in 2025.

Strengths:
• Industry-leading revenue and improving profitability: Achieved sales of $28.4 billion in 2025, with adjusted EBITDA surging 13% year-on-year to $4.4 billion, and EBITDA margin expanding by 1.9 percentage points to 15.4%, driven by portfolio optimization and strict cost management.
• Unrivaled R&D pipeline with over 1,200 regulatory approvals: Next-generation active ingredients ADEPIDYN® and TYMIRIUM® secured over 1,200 new product registrations globally in 2025, maintaining one of the strongest patent moats in the agrochemical sector.
• Strong penetration in the Chinese market and expansion of the biologics business: Syngenta Group China contributed $8.3 billion in revenue, with the biologics division achieving double-digit growth. A new state-of-the-art biologics production facility in Orangeburg, South Carolina, supports this foundation.

Weaknesses:
• Price pressure from generic agrochemicals in Latin America: In Latin America, particularly in the Brazilian soybean and corn markets, aggressive competition from low-cost generic agrochemicals led to a roughly 3% decline in sales, necessitating ongoing pricing strategy reviews.
• Complex organizational structure and lack of direct listing: As an unlisted parent company, Syngenta Group faces challenges of lower transparency in capital markets and higher financing complexity compared to directly listed peers.